Olr401 inhibitors represent a class of compounds that specifically interact with the Olr401 protein, a member of the olfactory receptor family. These inhibitors are characterized by their ability to bind to the Olr401 receptor, which is part of the extensive G-protein-coupled receptor (GPCR) superfamily, known for its significant role in signal transduction. The Olr401 receptor, being a part of the olfactory system, is involved in the detection of specific odorants, playing a crucial role in the sensory perception of smells. The molecular architecture of Olr401 inhibitors is designed to precisely target the binding sites of the Olr401 receptor, thereby modulating its activity. This specificity is often achieved through intricate structural designs that mimic or compete with the natural ligands of the receptor. The development of Olr401 inhibitors requires a deep understanding of the receptor's binding pocket, including key amino acid residues that contribute to ligand-receptor interactions.
The chemical properties of Olr401 inhibitors are highly variable and depend on the structural characteristics necessary to achieve effective receptor binding. These compounds can range from small organic molecules to more complex structures with multiple functional groups that allow for high-affinity binding. The design of these inhibitors often involves a combination of computational modeling, to predict receptor-ligand interactions, and synthetic chemistry techniques, to optimize the compounds for maximum efficacy and specificity. The physicochemical properties such as solubility, stability, and molecular weight are meticulously considered during the synthesis process to ensure that the inhibitors maintain their activity under various experimental conditions. Additionally, these inhibitors are typically subjected to rigorous characterization methods, including NMR spectroscopy, X-ray crystallography, and mass spectrometry, to confirm their structure and binding efficacy. Understanding the nuances of how Olr401 inhibitors interact with their target receptor provides valuable insights into the broader field of olfactory receptor modulation and GPCR-related research.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Aripiprazole | 129722-12-9 | sc-207300 sc-207300A sc-207300B | 100 mg 1 g 5 g | $179.00 $212.00 $1037.00 | 3 | |
Atypical antipsychotic, can indirectly modulate GPCR signaling through dopamine and serotonin receptor pathways, potentially impacting Olr401. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $109.00 $322.00 | 3 | |
Phosphodiesterase inhibitor, might influence GPCR signaling indirectly through cAMP modulation, impacting Olr401. | ||||||
Domperidone | 57808-66-9 | sc-203032 sc-203032A | 50 mg 250 mg | $61.00 $287.00 | 2 | |
Dopamine antagonist, could alter GPCR signaling, potentially impacting Olr401. | ||||||
Ivabradine hydrochloride | 148849-67-6 | sc-507513 | 10 mg | $120.00 | ||
If channel inhibitor, can modulate GPCR signaling indirectly through cardiac electrophysiological effects, impacting Olr401. | ||||||
trans Lacidipine | 103890-78-4 | sc-213066 | 10 mg | $153.00 | ||
Calcium channel blocker, might affect GPCR signaling through calcium modulation, potentially impacting Olr401. | ||||||
Nebivolol | 99200-09-6 | sc-279910 | 100 mg | $803.00 | 1 | |
Beta-1 adrenergic receptor antagonist, could influence GPCR signaling pathways, potentially impacting Olr401. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $82.00 $333.00 | 1 | |
Serotonin receptor antagonist, may modulate GPCR signaling, potentially affecting Olr401. | ||||||
Rabeprazole | 117976-89-3 | sc-204872 sc-204872A | 10 mg 25 mg | $349.00 $620.00 | 2 | |
Proton pump inhibitor, can indirectly affect GPCR signaling through gastric acid modulation, impacting Olr401. | ||||||
Salmeterol | 89365-50-4 | sc-224277 sc-224277A | 10 mg 50 mg | $186.00 $562.00 | 1 | |
Long-acting beta-2 adrenergic agonist, might indirectly modulate GPCR signaling, impacting Olr401. | ||||||
Valsartan | 137862-53-4 | sc-220362 sc-220362A sc-220362B | 10 mg 100 mg 1 g | $40.00 $92.00 $122.00 | 4 | |
Angiotensin II receptor antagonist, can indirectly modulate GPCR signaling, potentially impacting Olr401. | ||||||